We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Sight Diagnostics

Sight Diagnostics is a blood diagnostic company that combines machine vision and AI to improve health through fast, c... read more Featured Products: More products

Download Mobile App





Machine Vision-Based Blood Analyzer Supports Validation of AI-based COVID Screening System

By LabMedica International staff writers
Posted on 15 Mar 2021
A machine vision-based blood analyzer has been made part of an assessment of an AI-based test to rapidly screen for COVID-19 in patients arriving in emergency departments.

Sight Diagnostics (Tel Aviv, Israel) has deployed Sight OLO at the John Radcliffe Hospital - part of the Oxford University Hospitals NHS Foundation Trust (Oxford, UK) that allows rapid FBC testing, in minutes, for patients attending the emergency departments and is supporting validation of a rapid AI triage system for COVID-19. More...
Sight OLO enables faster predictions to be generated by Oxford University’s ‘CURIAL AI’ screening test, which leverages patients’ routine vital signs and FBC results to predict the likelihood of a patient having COVID-19.

Developed by a cross-disciplinary team at Oxford University, the CURIAL algorithm has proven to be an effective triage tool that can rule-out COVID-19 within the first hour of patients coming to the hospital. Polymerase Chain Reaction (PCR) tests typically have a turnaround time of 12-48 hours and require specialist equipment and staff, while the more rapid lateral flow assays and antigen tests have produced mixed efficacy results. With CURIAL, Sight OLO could allow staff in emergency rooms to receive an accurate prediction to rule-out COVID-19 in under 30 minutes. About the size of a toaster oven, Sight OLO is compact and uses a cartridge-based system that does not require external reagents or routine calibration and maintenance, making it simple to set-up and operate wherever FBC is needed.

“Having accurate FBC results in minutes, from OLO, would help CURIAL make predictions even sooner, potentially reducing care delays and supporting infection control within hospitals. Our goal is to get the right treatment to patients sooner by helping rule-out Covid at triage for a majority of patients who don’t have the infection,” said Dr. Andrew Soltan, an Academic Clinician and a Machine Learning Researcher at Oxford University. “This project shows that artificial intelligence can work with rapid diagnostics to help us select the best care pathways and minimize risks of spreading the infection in hospitals.”

“We’re proud to collaborate with a cutting-edge institution like Oxford University on their CURIAL analysis program to help manage the effects of the pandemic,” said Yossi Pollak, CEO and Co-founder of Sight Diagnostics. “We see time and again when FBC results are made available to clinicians quickly and easily, patient care models are reconfigured for the better. The CURIAL project is a beacon of what’s possible, and we are keen to support other health institutions by enabling access to fast, convenient and accurate FBC through OLO.”

Related Links:
Oxford University Hospitals NHS Foundation Trust
Sight Diagnostics



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.